Xcout Intel
CardioFocus, Inc.
CardioFocus, Inc. is a medical device company headquartered in Marlborough, Massachusetts. The firm is dedicated to advancing ablation treatment for cardiac arrhythmias.
Subscribe to see CardioFocus, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
CardioFocus, Inc. at a glance
CardioFocus, Inc. is a medical devices company headquartered in United States, founded in 1990. Its most recent funding round, Series C, raised $4M in March 2022. Xcout tracks 6 named people at CardioFocus, Inc., including Stephan S. Ogilvie (CEO).
CardioFocus, Inc. leadership
- Stephan S. OgilvieCEO
- Curt EysterChief Technology Officer
- Pete BellSVP, Global Business Development
- Ian ChristiansonVice President, Regulatory, Quality, and Clinical Affairs
- Jerry MelskyVice President, Engineering
- Scott FletcherVice President, Finance and Administration
CardioFocus, Inc. funding rounds
The 4 most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series C | $4M | 6 named | |
| SEC Form D filing | $12M | — | |
| SEC Form D filing | $8M | — | |
| — | $55M | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
CardioFocus, Inc. competitors
A few of CardioFocus, Inc.'s closest competitors — see the full list of competitors and alternatives →
Acutus Medical is a medical device and healthcare technology company focused on arrhythmia management. The company designs, manufactures, and markets tools and minimally invasive cardiac catheters for catheter-based ablation procedures to diagnose and treat irregular heart rhythms and complex cardiac arrhythmias.
Shanghai MicroPort EP MedTech Co., Ltd. is a MicroPort company focused on electrophysiology (EP) medical devices, including systems and catheters used for cardiac arrhythmia diagnosis and catheter ablation treatment. Its products serve hospitals and cardiac electrophysiology physicians, primarily in clinical cardiovascular care.
CardiaLen, Inc. is a medical device company formed in 2009 with headquarters in Minneapolis, Minnesota, focusing on the development of novel therapies and electrical stimulation devices for treating atrial and ventricular arrhythmias.
Adagio Medical Holdings, Inc. is an emerging medical device firm focused on pioneering and commercializing innovative ablation technologies. Its core mission is to provide therapeutic solutions for various cardiac rhythm disorders, including but not limited to atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's current product portfolio showcases advanced offerings such as the iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and its complementary accessories, the vCLAS ventricular ULTC catheter, and the Cryopulse atrial pulsed-field cryoablation catheter, also available with associated accessories. This entity, which commenced operations in 2011, has its principal office situated in Laguna Hills, California.
Corfigo develops medical devices for cardiac surgery, specifically the HeartPad XLT Cryoablation System. The system utilizes liquid helium cryothermal energy to ablate diseased cardiac tissue from the heart's outer surface while protecting adjacent structures.
Get CardioFocus, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on CardioFocus, Inc. in Xcout Intel
- 6 named people with titles, LinkedIn and board committees
- 10 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access